 |
|
Bone drug could help prevent the spread of breast cancer
May 19, 2008Maintaining bone density could be a key to decreasing the spread of cancer in women with locally advanced breast cancer, according to research at Washington University School of Medicine in St. Louis.
Bones are common sites for the spread, or metastasis, of breast cancer. Scientists here found that women treated for stage II/III breast cancer who also received a bone strengthening drug were less likely to have breast tumor cells growing in their bones after three months. The bone-strengthening drug used was zoledronic acid, a drug that decreases bone turnover and reduces bone fractures in patients with osteoporosis.
The findings will be reported June 3 at 11 a.m. CT at the 2008 American Society of Clinical Oncology Annual Meeting in Chicago.
"Tumor cells are continually being released from the primary tumor," says lead author Rebecca Aft, M.D., Ph.D., associate professor of surgery, faculty member of the Siteman Cancer Center and a Washington University breast surgeon at Barnes Jewish Hospital. "It is thought that the bone marrow harbors these cells and that these cells are likely to evolve into metastatic disease. We think that zoledronic acid changes the bone marrow so that cancer cells are unable to lodge there."
The researchers randomly assigned 120 women being treated for clinical stage II/III breast cancer to receive 4 milligrams of zoledronic acid intravenously every three weeks for one year, starting with their first cycle of chemotherapy, or to receive no zoledronic acid. Stage II/III cancer means the primary tumor has spread into lymph nodes or other areas near the breast.
At the time of diagnosis, none of the patients had evidence of metastatic disease on computed tomography (CT) and/or positron emission tomography (PET) scans. But bone marrow samples showed that about 40 percent of the patients had detectable breast tumor cells in the bone marrow.
Prior research has shown that women with even minuscule clusters of breast tumor cells - called micrometastases - in their bone marrow at the time of their diagnosis have an increased risk of developing large metastatic tumors later.
The researchers took bone marrow samples again three months and one year after treatment began. Only 23 percent of women who got zoledronic acid had tumor cells after three months compared to 36 percent of those who didn't get the drug. This result did not reach statistical significance.
Of women who started with no tumor cells in their bone marrow, 88 percent remained free of tumor cells in their bone marrow if they got zoledronic acid, compared to 70 percent of those who did not receive the drug. This result approached statistical significance. The one-year results are not yet available.
Aft says that women who receive chemotherapy for breast cancer have increased rates of bone turnover, which can release growth factors and produce a favorable environment for cancer cells. The suppression of bone turnover by zoledronic acid or other bisphosphonate drugs could make bones less friendly surroundings for cancer.
"We found that patients who are negative for tumor cells in bone marrow have a very good chance of staying negative if they take zoledronic acid," Aft says. "If longer follow up shows that women without tumor cells in their bones do not go on to develop metastatic disease, then it would be reasonable to say that bisphosphonates will likely benefit women with locally advanced breast cancer."
Washington University School of Medicine
"Tumor cells are continually being released from the primary tumor," says lead author Rebecca Aft, M.D., Ph.D., associate professor of surgery, faculty member of the Siteman Cancer Center and a Washington University breast surgeon at Barnes Jewish Hospital. "It is thought that the bone marrow harbors these cells and that these cells are likely to evolve into metastatic disease. We think that zoledronic acid changes the bone marrow so that cancer cells are unable to lodge there."
The researchers randomly assigned 120 women being treated for clinical stage II/III breast cancer to receive 4 milligrams of zoledronic acid intravenously every three weeks for one year, starting with their first cycle of chemotherapy, or to receive no zoledronic acid. Stage II/III cancer means the primary tumor has spread into lymph nodes or other areas near the breast.
At the time of diagnosis, none of the patients had evidence of metastatic disease on computed tomography (CT) and/or positron emission tomography (PET) scans. But bone marrow samples showed that about 40 percent of the patients had detectable breast tumor cells in the bone marrow.
Prior research has shown that women with even minuscule clusters of breast tumor cells - called micrometastases - in their bone marrow at the time of their diagnosis have an increased risk of developing large metastatic tumors later.
The researchers took bone marrow samples again three months and one year after treatment began. Only 23 percent of women who got zoledronic acid had tumor cells after three months compared to 36 percent of those who didn't get the drug. This result did not reach statistical significance.
Of women who started with no tumor cells in their bone marrow, 88 percent remained free of tumor cells in their bone marrow if they got zoledronic acid, compared to 70 percent of those who did not receive the drug. This result approached statistical significance. The one-year results are not yet available.
Aft says that women who receive chemotherapy for breast cancer have increased rates of bone turnover, which can release growth factors and produce a favorable environment for cancer cells. The suppression of bone turnover by zoledronic acid or other bisphosphonate drugs could make bones less friendly surroundings for cancer.
"We found that patients who are negative for tumor cells in bone marrow have a very good chance of staying negative if they take zoledronic acid," Aft says. "If longer follow up shows that women without tumor cells in their bones do not go on to develop metastatic disease, then it would be reasonable to say that bisphosphonates will likely benefit women with locally advanced breast cancer."
Washington University School of Medicine
Bone Marrow Current Events and Bone Marrow News RSSBone Implant Offers Hope for Skull Deformities
A synthetic bone matrix offers hope for babies born with craniosynostosis, a condition that causes the plates in the skull to fuse too soon.
U of M researchers find 2 units of umbilical cord blood reduce risk of leukemia recurrence
A new study from the Masonic Cancer Center, University of Minnesota shows that patients who have acute leukemia and are transplanted with two units of umbilical cord blood (UCB) have significantly reduced risk of the disease returning.
Scientists successfully reprogram blood cells
Researchers have transplanted genetically modified hematopoietic stem cells into mice so that their developing red blood cells produce a critical lysosomal enzyme -preventing or reducing organ and central nervous system damage from the often-fatal genetic disorder Hurler's syndrome.
Immune therapy can protect against or treat later lymphoma
Specially developed immune system cells that target the common Epstein-Barr virus can protect immune-suppressed bone marrow transplant recipients against lymph system disease and cancers that arise from the viral infection.
Stem cell therapy may offer hope for acute lung injury
Researchers at the University of Illinois at Chicago College of Medicine have shown that adult stem cells from bone marrow can prevent acute lung injury in a mouse model of the disease.
New insight in the fight against the Leishmania parasite
Professor Albert Descoteaux's team at Centre INRS - Institut Armand-Frappier has gained a better understanding of how the Leishmania donovani parasite manages to outsmart the human immune system and proliferate with impunity, causing visceral leishmaniasis, a chronic infection that is potentially fatal if left untreated.
2-million-year-old evidence shows tool-making hominins inhabited grassland environments
In an article published in the open-access, peer-reviewed journal PLoS ONE on October 21, 2009, Dr Thomas Plummer of Queens College at the City University of New York, Dr Richard Potts of the Smithsonian Institution National Museum of Natural History and colleagues report the oldest archeological evidence of early human activities in a grassland environment, dating to 2 million years ago.
Mice regain ability to extend telomeres suggesting potential for dyskeratosis congenita therapy
The human genetic disease dyskeratosis congenita (DKC) is an autosomal dominant disease that leads to abnormalities in tissues with a rapid cell turnover - the skin, nails, bone marrow, lungs and gut.
Strategy for mismatched stem cell transplants triggers protection against graft-vs.-host disease
A new technique being tested in stem-cell transplants from imperfectly matched donors has revealed a striking, unforeseen response that can suppress graft-versus-host disease, a common and dangerous complication of mismatched transplants, report scientists from Dana-Farber Cancer Institute.
Multivisceral transplant survival rates improve with new treatment, says Pittsburgh study
Data from the largest single-center experience of adult and pediatric intestinal and multivisceral transplantation show that survival rates have improved with the advent of innovative surgical techniques, novel immunosuppressive protocols and better post-operative management.
More Bone Marrow Current Events and Bone Marrow News Articles
 |
Bone Marrow Immunohistochemistry by Emina Emilia Torlakovic (Author), Kikkeri N Naresh (Author), Richard D Brunning (Author) Bone Marrow IHC provides a rich collection of color illustrations that demonstrate the diagnostic features of antibodies applicable to bone marrow tissue. Each of the antibodies illustrated in the volume includes a systematic description that details an expected reaction profile in both normal bone marrow cells and neoplastic cells, as well as authoritative advice about avoiding potential diagnostic pitfalls and technical problems related to the antibodies and tissue processing. A completely practical volume for pathologists and pathology residents alike, Bone Marrow IHC presents a methodological approach. Included are critical reviews of most of the IHC tests in use today, as well as summaries of expected reactivities in normal and diseased bone marrow. Also included is information... |
 |
Lamaur Bone Marrow Conditioner by Lamaur Deep Penetrating Treatment after coloring, bleaching, perming, or any other salon service. For proper hair maintenance, use on a regular once-a-week basis to keep hair moisturized, conditioned and in manageable condition. For severely damaged hair, use every other day. |
 |
Milk-Bone Original Crunchy Marrow Filled Treats For Dogs by Milk Bone Milk-Bone Original Crunchy Marrow Filled Treats For Dogs are made with succulent bone marrow that dogs crave! Their small size make them perfect for training. |
 |
The Marrow of a Bone by Dir en grey Following up to the world-wide smash hit album, 'Withering To Death', Dir en grey is releasing, 'The Marrow of a Bone.' It includes the single track, 'Agitated Screams of Maggots', 'CLEVER SLEAZOID', 'Ryojoku no Ame,' and more! This Limited edition also includes bonus CD with classical arrangements of the album tracks. Sony. 2006. |
![The Marrow Of A Bone [Explicit]](http://ecx.images-amazon.com/images/I/41Dy7rkxNVL._SL160_.jpg) |
The Marrow Of A Bone [Explicit] Dir En Grey (Primary Contributor) |
 |
Bone Marrow Pathology by Anesoft (Author), Kathryn Foucar (Author) Already a standard in the field, the new edition of Bone Marrow Pathology incorporates the latest WHO classification system to present an integrative approach that fosters superior interpretation. Illustrated with more than 800 color images integrated into the discussions, the text reviews basic epidemiologic, clinical and hematologic findings in disorders, as well as addressing smear and section interpretation. This practical tool includes tips, clues, and caveats in diagnosis. |
 |
Bone Marrow Donation Awareness Ribbon Mouse Pad by MyHeritageWear.com The Bone Marrow Donation Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the Bone Marrow Donation Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your Bone Marrow Donation Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness! |
|
The New Normal Life After Bone Marrow Stem Cell Transplant a compelling story of six transplant survivors | |
 |
5½" Marrow Action Figure with Detachable Bone Weaponry! - Marvel Comics X-Men Generation X - Gen-X Display Base Included! by Toy Biz, Inc. To survive a devastating attack upon them, a group of Morlocks - exiled mutants living beneath the street of Manhattan - were teleported to another dimension. Enraged at being driven from their home, a twisted young woman called Marrow devised a means to return to Earth and exact revenge upon those she held responsible: humans! Dead set on destruction, Marrow will use her mutant ability to rend bone weapons from her own body against anyone who gets in her way! |
 |
Allegiance Tray Biopsy, Bone Marrow 11gx4" 10/cs by Allegiance ALLEGIANCE TRAY BIOPSY, BONE MARROW 11GX4" 10/CS : ALLEGIANCE TRAY BIOPSY, BONE MARROW 11GX4" 10/CS |
| © 2009 BrightSurf.com |